Rationale and Clinical Results of Inhibiting Interleukin-5 for the Treatment of Severe Asthma

[1]  J. Bird,et al.  Mepolizumab for Severe Eosinophilic Asthma (DREAM): A Multicentre, Double-Blind, Placebo-Controlled Trial , 2013, Pediatrics.

[2]  Shu-Juan Jiang,et al.  Efficacy of Anti-Interleukin-5 Therapy with Mepolizumab in Patients with Asthma: A Meta-Analysis of Randomized Placebo-Controlled Trials , 2013, PloS one.

[3]  I. Pavord,et al.  Omalizumab: NICE to USE you, to LOSE you NICE , 2012, Thorax.

[4]  Aasia I. Ghazi,et al.  Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma , 2012, Expert opinion on biological therapy.

[5]  S. Willsie.  Reslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-Controlled Study , 2012 .

[6]  S. Johnston,et al.  Asthma exacerbations: Origin, effect, and prevention , 2011, Journal of Allergy and Clinical Immunology.

[7]  L. Boulet,et al.  Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. , 2011, American journal of respiratory and critical care medicine.

[8]  K. Takatsu.  Interleukin-5 and IL-5 receptor in health and diseases , 2011, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[9]  Martyn R Partridge,et al.  Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. , 2010, The Journal of allergy and clinical immunology.

[10]  W. Busse,et al.  Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. , 2010, The Journal of allergy and clinical immunology.

[11]  A. August,et al.  The role of eosinophils in allergic airway inflammation. , 2010, Discovery medicine.

[12]  S. Willsie.  Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia , 2010 .

[13]  S. Wenzel.  Eosinophils in asthma--closing the loop or opening the door? , 2009, The New England journal of medicine.

[14]  A. Abba.  Exhaled nitric oxide in diagnosis and management of respiratory diseases , 2009, Annals of thoracic medicine.

[15]  I. Pavord,et al.  Sputum IL-5 Concentration Is Associated with a Sputum Eosinophilia and Attenuated by Corticosteroid Therapy in COPD , 2009, Respiration.

[16]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[17]  B. Thiers.  Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab , 2009 .

[18]  Martyn R Partridge,et al.  British Guideline on the Management of Asthma , 2008, Thorax.

[19]  L. Boulet,et al.  Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. , 2008, American journal of respiratory and critical care medicine.

[20]  J. Parkin,et al.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab. , 2008, The New England journal of medicine.

[21]  B. Chiang,et al.  Small interfering RNA against interleukin-5 decreases airway eosinophilia and hyper-responsiveness , 2008, Gene Therapy.

[22]  P. Weller,et al.  Human Eosinophils Express Functional Notch Ligands , 2008 .

[23]  P. J. Barnes,et al.  Global strategy for asthma management and prevention: GINA executive summary , 2008, European Respiratory Journal.

[24]  W. Busse,et al.  A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.

[25]  S. Phipps,et al.  Eosinophil trafficking in allergy and asthma. , 2007, The Journal of allergy and clinical immunology.

[26]  S. Holgate,et al.  The mechanisms, diagnosis, and management of severe asthma in adults , 2006, The Lancet.

[27]  R. Strunk,et al.  Omalizumab for asthma. , 2006, The New England journal of medicine.

[28]  J. Vondráček,et al.  Strategy Aimed at Reduction of Sputum Eosinophils Decreases Exacerbation Rate in Patients with Asthma , 2006, The Journal of international medical research.

[29]  L. Boulet,et al.  Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations , 2006, European Respiratory Journal.

[30]  C. Brightling,et al.  Eosinophilic airway inflammation in COPD , 2006, International journal of chronic obstructive pulmonary disease.

[31]  I. Pavord,et al.  Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness , 2006, European Respiratory Journal.

[32]  S. Wenzel,et al.  Severe asthma in adults. , 2005, American journal of respiratory and critical care medicine.

[33]  E. Israel,et al.  Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. , 2005, The Journal of allergy and clinical immunology.

[34]  S. Orkin,et al.  A Critical Role for Eosinophils in Allergic Airways Remodeling , 2004, Science.

[35]  E. Lenkiewicz,et al.  Defining a Link with Asthma in Mice Congenitally Deficient in Eosinophils , 2004, Science.

[36]  K. Takatsu,et al.  Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice. , 2004, American journal of respiratory cell and molecular biology.

[37]  S. Phipps,et al.  Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. , 2003, The Journal of clinical investigation.

[38]  A. Kay,et al.  Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. , 2003, American journal of respiratory and critical care medicine.

[39]  I. Pavord,et al.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.

[40]  P. Renzi,et al.  Inhibition of antigen-induced eosinophilia and airway hyperresponsiveness by antisense oligonucleotides directed against the common beta chain of IL-3, IL-5, GM-CSF receptors in a rat model of allergic asthma. , 2002, American journal of respiratory and critical care medicine.

[41]  P. Barnes.  Glucocorticoids and asthma. , 2002, Ernst Schering Research Foundation workshop.

[42]  K. Chung,et al.  Evidence for systemic rather than pulmonary effects of interleukin-5 administration in asthma , 2001, Thorax.

[43]  C. Jenkins,et al.  Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. , 2001, American journal of respiratory and critical care medicine.

[44]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[45]  A J Wardlaw,et al.  Eosinophils in asthma and other allergic diseases. , 2000, British medical bulletin.

[46]  S. Wenzel,et al.  Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. , 1999, American journal of respiratory and critical care medicine.

[47]  Christine Jenkins,et al.  Differences between asthma exacerbations and poor asthma control , 1999, The Lancet.

[48]  D. Postma,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. , 1997, The New England journal of medicine.

[49]  H. Xu,et al.  Infiltration of eosinophils into the asthmatic airways caused by interleukin 5. , 1997, American journal of respiratory cell and molecular biology.

[50]  P. Weller.  Human eosinophils. , 1997, The Journal of allergy and clinical immunology.

[51]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[52]  S. Oddera,et al.  Airway eosinophilic inflammation, epithelial damage, and bronchial hyperresponsiveness in patients with mild‐moderate, stable asthma , 1996, Allergy.

[53]  P. Foster,et al.  Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model , 1996, The Journal of experimental medicine.

[54]  D. Proud,et al.  Human eosinophil-granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation. , 1995, The Journal of clinical investigation.

[55]  P. Barnes,et al.  Inhaled glucocorticoids for asthma. , 1995, The New England journal of medicine.

[56]  A. Miyajima,et al.  Receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3, and interleukin-5 , 1993 .

[57]  A. Malmström,et al.  Eosinophil cationic protein alters proteoglycan metabolism in human lung fibroblast cultures. , 1992, European journal of cell biology.

[58]  M. Strath,et al.  Eosinophilia in transgenic mice expressing interleukin 5 , 1990, The Journal of experimental medicine.

[59]  J. Bousquet,et al.  Eosinophilic inflammation in asthma. , 1990, The New England journal of medicine.

[60]  A. Wardlaw,et al.  IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11/18)-dependent manner. , 1990, Immunology.

[61]  H. Kita,et al.  Regulatory effect of cytokines on eosinophil degranulation. , 1990, Journal of immunology.

[62]  W. Owen,et al.  IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. , 1989, Journal of immunology.

[63]  I. G. Young,et al.  Molecular organization of the cytokine gene cluster, involving the human IL-3, IL-4, IL-5, and GM-CSF genes, on human chromosome 5. , 1989, Blood.

[64]  D. Loegering,et al.  Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. , 1989, The American review of respiratory disease.

[65]  A. Wardlaw,et al.  Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity. , 1988, The American review of respiratory disease.

[66]  G. Klaus,et al.  Eosinophil differentiation factor also has B-cell growth factor activity: proposed name interleukin 4. , 1986, Proceedings of the National Academy of Sciences of the United States of America.